Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

339.50p
   
  • Change Today:
    -8.00p
  • 52 Week High: 1,582.00p
  • 52 Week Low: 320.00p
  • Currency: UK Pounds
  • Shares Issued: 3.60m
  • Volume: 7,700
  • Market Cap: £12.24m
  • RiskGrade: 340

HEMO Overview

Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.
Competitors: Okyo Pharma Limited , Nuformix

Key Personnel

CEO: Vladislav Sandler Ph.D.
Non-Executive Chairman: Marc Feldmann
Non-Executive Dir: Peter Redmond, Alexis M. Sandler

Contact Details

Address: 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Website: http://hemogenyx.com/

Listings

Sector: Pharma and Biotech(LSE)
Overseas Listings: BATSLON:SILFL
ISIN: GB00BQVXM815

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HEMO Market Data

Currency UK Pounds
Share Price 339.50p
Change Today -8.00p
% Change -2.30 %
52 Week High 1,582.00p
52 Week Low 320.00p
Volume 7,700
Shares Issued 3.60m
Market Cap £12.24m
RiskGrade 340

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.19% below the market average44.19% below the market average44.19% below the market average44.19% below the market average44.19% below the market average
62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average
Price Trend
85.9% below the market average85.9% below the market average85.9% below the market average85.9% below the market average85.9% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for 10-Feb-2025

Time Volume / Share Price
15:47 2 @ 344.00p
16:20 3 @ 340.00p
15:47 2 @ 344.00p
15:30 400 @ 335.60p
14:11 92 @ 335.50p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page